| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRIM.2019.101230 |
| P698 | PubMed publication ID | 31398461 |
| P50 | author | Yoichi Kakuta | Q82715139 |
| P2093 | author name string | Kazunari Tanabe | |
| Hideki Ishida | |||
| Kohei Unagami | |||
| Masayoshi Okumi | |||
| Katsunori Miyake | |||
| Miyuki Furusawa | |||
| P2860 | cites work | Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 |
| Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. | Q35027253 | ||
| IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury | Q36417907 | ||
| Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. | Q36827985 | ||
| The role of complement in the early immune response to transplantation. | Q38013049 | ||
| Relationship between Mean Fluorescence Intensity and C1q/C3d-fixing capacities of anti-HLA antibodies | Q38965721 | ||
| Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation. | Q40452964 | ||
| Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies. | Q40621135 | ||
| Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. | Q40769068 | ||
| ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management | Q40915460 | ||
| Five-year outcomes in living donor kidney transplants with a positive crossmatch. | Q45351621 | ||
| Positive cross-match living donor kidney transplantation: longer-term outcomes | Q46134337 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience | Q46155740 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies | Q47147931 | ||
| Clinical Utility of Complement Dependent Assays in Kidney Transplantation | Q47266435 | ||
| Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. | Q50618048 | ||
| Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation. | Q51479808 | ||
| Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. | Q51563025 | ||
| Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. | Q53388671 | ||
| Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. | Q55509898 | ||
| Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure | Q63866084 | ||
| Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation | Q71738460 | ||
| Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg) | Q74815832 | ||
| Results of positive cross-match transplantation in African American renal transplant recipients | Q80482514 | ||
| Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody | Q81556677 | ||
| Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss | Q82554497 | ||
| C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation | Q82659907 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients | Q87006000 | ||
| Outcome of the risk-stratified desensitization protocol in donor-specific antibody-positive living kidney transplant recipients: a retrospective study | Q88420662 | ||
| Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies | Q90224907 | ||
| P304 | page(s) | 101230 | |
| P577 | publication date | 2019-08-06 | |
| P1433 | published in | Transplant Immunology | Q15758510 |
| P1476 | title | Prognostic value of C3d-fixing, preformed donor-specific antibodies in crossmatch-positive living kidney transplantation | |
| P478 | volume | 57 |
Search more.